Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CentreStone Ventures Inc.: Investment Made in Medicure Inc.


WINNIPEG, Manitoba -- CentreStone Ventures Inc.

Dr. Albert D. Friesen, the CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of CentreStone Ventures Limited Partnership Fund ("CentreStone") announces that as a result of the purchase today of 887,500 common shares of Medicure Inc. ("Medicure") by CentreStone, Dr. Friesen now has ownership or control over 6,933,315 common shares of Medicure representing approximately 10.4% of the issued and outstanding common shares of Medicure. Medicure is listed on the Toronto Stock Exchange Toronto Stock Exchange (TSE)

Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options.
 under the trading symbol Trading symbol

See: Ticker symbol
 "MPH".

Prior to the acquisition, Dr. Friesen owned, directly and indirectly, or exercised control or direction over an aggregate of 6,045,815 common shares of Medicure.

The common shares of Medicure were acquired for investment purposes. Dr. Friesen has not made any determination with respect to future ownership of or control over any additional shares. Dr. Friesen may in the future acquire additional shares of Medicure in the market or through private or other transactions, sell all or some portion of the shares of Medicure he owns, or enter into derivative derivative: see calculus.
derivative

In mathematics, a fundamental concept of differential calculus representing the instantaneous rate of change of a function.
  or other transactions with respect to his shares of Medicure.

A copy of the early warning report with additional details will be filed via SEDAR SEDAR System for Electronic Document Analysis and Retrieval
SEDAR Southeast Data, Assessment, and Review
 at www.SEDAR.com.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Apr 29, 2005
Words:199
Previous Article:PMA Management Corp. Names Michael MacAulay Vice President of Sales.
Next Article:Phibro Animal Health Corporation Announces the Sale of Wychem Ltd.



Related Articles
MEDICURE GETS U.S. PATENT NOTICE OF ALLOWANCE FOR THERAPEUDICS.
MEDICURE EXPANDS INTELLECTUAL PROPERTY POSITION.
MEDICURE APPROVED TO INITIATE PHASE II/III HYPERTENSION TRIALS.
MEDICURE GETS FDA/TPD APPROVALS FOR MC-1 PHASE II TRIAL.
Medicure to Present at Two Major Biotech Conferences.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles